Shanghai Henlius Biotech, Inc. Class H (2696) Price & Analysis

Compare

3 Followers

2696 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$15.20 - HK$92.00

Previous CloseN/A

Volume849.10K

Average Volume (3M)1.61M

Market Cap

HK$42.18B

Enterprise ValueHK$31.74B

Total Cash (Recent Filing)HK$772.96M

Total Debt (Recent Filing)HK$3.65B

Price to Earnings (P/E)47.4

Beta0.57

Next Earnings

Aug 25, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding163,428,540

10 Day Avg. Volume1,966,560

30 Day Avg. Volume1,613,595

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$97.75

Price Target Upside25.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PerformanceHenlius has transitioned into a profit-generating company by leveraging its broad and growing network of global partnerships, actively expanding its presence in the international biosimilar market.

Market ExpansionSerplulimab has received approvals in EU and Southeast Asia, representing a compelling opportunity in first-line MSS CRC.

Product DevelopmentHLX43 has demonstrated competitive early efficacy for IO-resistant NSCLC, showing consistent anti-tumor activity.

Bears Say

Competitive LandscapeHLX22 is viewed as a strong alternative for first-line HER2+ gastric cancer, but it faces competition from current standard treatments in this indication.

Shanghai Henlius Biotech, Inc. Class H News

Shanghai Henlius Biotech Gains EU Approval for Osteoporosis Treatments

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an announcement. Shanghai Henlius Biotech, Inc. announced...

3d ago

2696

Shanghai Henlius Biotech Advances HLX43 Clinical Trials for Lung Cancer

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) just unveiled an update. Shanghai Henlius Biotech, Inc. has...

4d ago

2696

Shanghai Henlius Biotech’s HLX17 Receives FDA Approval for Clinical Trials

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has provided an update. Shanghai Henlius Biotech, Inc. announced...

14d ago

2696

Shanghai Henlius Biotech Receives FDA Approval for Two Biosimilars

An announcement from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) is now available. Shanghai Henlius Biotech,...

21d ago

2696

Shanghai Henlius Biotech Confirms Leadership Continuity with Board Re-appointments

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has issued an update. Shanghai Henlius Biotech, Inc. announced...

24d ago

2696

Shanghai Henlius Biotech Announces Board Composition and Roles

The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech,...

24d ago

2696

Shanghai Henlius Biotech Grants Options and RSUs to Boost Performance

Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) just unveiled an announcement. Shanghai Henlius Biotech, Inc. announced...

24d ago

2696

Shanghai Henlius Biotech: Strong Financial Performance and Promising Product Pipeline Drive Buy Rating

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H,...

25d ago

Shanghai Henlius Biotech Reports Growth and Expands Global Reach in 2025

The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech,...

28d ago

2696

Shanghai Henlius Biotech Advances HLX43 Clinical Trials in the US

The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ). Shanghai Henlius Biotech,...

1M ago

2696

2696 FAQ

What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?

Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$15.20 and its highest was HK$92.00 in the past 12 months.

What is Shanghai Henlius Biotech, Inc. Class H’s market cap?

Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$42.18B.

When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?

Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Aug 25, 2025 which is 28 days ago.

How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?

Shanghai Henlius Biotech, Inc. Class H released its earnings results on Mar 24, 2025. The company reported HK$0.867 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.867.

Is Shanghai Henlius Biotech, Inc. Class H overvalued?

According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Shanghai Henlius Biotech, Inc. Class H pay dividends?

Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.

What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?

Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?

Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.

What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?

Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.132%.

Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?

Currently, no hedge funds are holding shares in HK:2696

Shanghai Henlius Biotech, Inc. Class H Stock Smart Score

Outperform

Fundamentals

Return on Equity

27.37%

Trailing 12-Months

Asset Growth

18.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. Class H (2696) is a leading biopharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of monoclonal antibody (mAb) biosimilars and innovative biologics. The company operates in the biotechnology and pharmaceutical sectors, focusing on providing affordable and high-quality biologic drugs to treat cancer, autoimmune diseases, and other serious conditions. Henlius is committed to enhancing global healthcare access through its robust pipeline of biosimilar and novel therapeutic products.

Shanghai Henlius Biotech, Inc. Class H (2696) Earnings & Revenues

Historic Earnings Reports

2696 Stock 12 Month Forecast

Average Price Target

HK$97.75

▲(25.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","98":"HK$98","31.25":"HK$31.3","53.5":"HK$53.5","75.75":"HK$75.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$97.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$97.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$97.75</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,31.25,53.5,75.75,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Aug<br/>2023","9":"May<br/>2024","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66,68.4423076923077,70.88461538461539,73.32692307692308,75.76923076923077,78.21153846153847,80.65384615384616,83.09615384615384,85.53846153846155,87.98076923076923,90.42307692307693,92.86538461538461,95.3076923076923,{"y":97.75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66,68.4423076923077,70.88461538461539,73.32692307692308,75.76923076923077,78.21153846153847,80.65384615384616,83.09615384615384,85.53846153846155,87.98076923076923,90.42307692307693,92.86538461538461,95.3076923076923,{"y":97.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66,68.4423076923077,70.88461538461539,73.32692307692308,75.76923076923077,78.21153846153847,80.65384615384616,83.09615384615384,85.53846153846155,87.98076923076923,90.42307692307693,92.86538461538461,95.3076923076923,{"y":97.75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.66,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.3,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.86,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.54,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.1,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.78,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.78,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.64,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.18,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >